| Prev Close | 29.97 |
| Day Low/High | 29.97 / 30.95 |
| 52 Wk Low/High | 8.83 / 30.16 |
Chemours Co. (CC)
30.12
NYSE
| Exchange | NYSE |
| Shares Outstanding | 165.17B |
| Market Cap | 4.95B |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
This Ugly Duckling Portfolio of 2019 Losers Grew Into a Beautiful Swan
The deep-value Tax-Loss Selling Recovery Portfolio of a dozen stocks handsomely outperformed the S&P 500 and Russell 2000 indices.
Late Surge Turns This Portfolio of Ugly Stocks Into Very Lovable Losers
Thanks to big gains by Tupperware Brands and GameStop these dozen stocks that languished in 2019 collectively are now up nicely since the portfolio's inception.
Renewed Life for the Tax Loss Selling Recovery Portfolio
The idea behind this annual 'experiment' is to identify potentially 'cheap' names with 3 attributes.
Updating My Annual Tax Loss Selling Recovery Portfolio
There's progress for sure, but still a long way to go. Things could be worse.
This Year's Tax-Loss-Selling Recovery Portfolio Is a Real Loser So Far
This experiment in trying to identify stocks that could come back after dismal year-ago performance isn't going well five months since its inception.
Jim Cramer: Oil Tanked, and We're in Uncharted Waters
Oil isn't really worthless and Amazon isn't the only retailer that will survive, but we are in a mixed up market thanks to Covid-19.
How We Doing? My 12 Potential Tax-Loss Selling Candidates
If investors reengage with these names in 2020, this could be an interesting set-up for market outperformance.
My Tax-Loss Selling Year-End Portfolio
In this portfolio, the goal is for the winners to more than offset the losers.
The Final 4 Unsightly Stocks Going Into My Next Tax-Loss Selling Portfolio
We'll track a dozen beaten-up stocks that could be subject to tax-loss selling at the end of 2019 to see whether they can stage comebacks in 2020.
This Chemical Stock Has the Formula for a Bullish Reversal
At the very end of December, the shorter of the two downtrend lines was violated suggesting a possible reversal at hand.
2 Beaten-Down Big-Caps for Value Shoppers
Kraft Heinz and DowDuPont spinoff Chemours offer attractive dividends and value potential.
Chemours Finally Has the Right Mix
The long correction in the chemicals company is over and traders can now go long on strength.
Make Some Bucks with Buckeye?
Beaten down pipeline MLP offers an attractive reward vs. risk profile.
'Lock and Roll' on Chemours
We'll roll our CC profits into a November call spread.
Chemours Has the Right Chemistry
The stock has been having a good year, but it's breaking out higher today.
Sometimes You Crave 'Junk Food' -- Even When Investing
At Libbey, the glass may be half empty, but it's likely to fill up again.
Sometimes You Crave 'Junk Food'
At Libbey, the glass may be half empty, but it's likely to fill up again.
These Stocks Have Changed Direction
Finding bullish and bearish reversals in the market.
Cramer: Are You Paying Attention to These Boring Companies? You Should
We ought to open our eyes to what we don't care about, to what's still made here.
Chemours: My Chemical/Technical Romance
CC has made a strong upside move but more gains are anticipated in the weeks ahead.
'Higher Value' Chemistry Key to Turnaround Says Chemours CEO
Chemours is up over 153% year-to-date and more than 50% since a short-seller targeted the chemical maker.
Anything These Guys Are Selling, I'm not Buying
When KKR and Apollo sell a stock it should be a huge red flag to investors to consider following suit.
Closing Bell: Chemours Spikes on Jury Verdict; U.S. Stocks Rally
Wall Street closed out the holiday-shortened week with a bang.
Cramer: Amazon Hits All-Time High Without Retail Folding
And that's distinctly good news for the overall market.
Here’s Short-Seller Andrew Left’s Latest Target
Shares of Chemours plunged on Friday on the heels of a bearish report written by short-seller Andrew Left of Citron Research.
Trending Tickers: SBUX , CC, BAC, ETFC, DNKN
U.S. markets falter Friday after an especially weak jobs report.
Short-Seller Cites 'Evil' of DuPont Spinoff Chemours
Andrew Left says he feels 'guilty' bringing up the stock issue when the humanitarian issue is much bigger.
